Immix Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	7.41	4.02	1.23	0.21	0.26
Research & Development	8.74	4.2	0.13	0.25	0.58
Operating Expenses	16.14	8.22	1.35	0.45	0.84
Operating Income	-16.14	-8.22	-1.35	-0.45	-0.84
Interest Expense / Income	0	0	0.18	0.1	0.11
Other Expense / Income	-0.74	-	22.85	0.57	-0
Pretax Income	-15.4	-8.22	-24.38	-1.13	-0.95
Income Tax	0.03	0.01	0.01	0.02	0.02
Net Income	-15.43	-8.23	-24.38	-1.15	-0.97
Shares Outstanding (Basic)	17	14	4	3	3
Shares Outstanding (Diluted)	17	14	4	3	3
Shares Change	24.87%	278.13%	8.82%	-	-
EPS (Basic)	-0.89	-0.59	-6.64	-0.34	-0.29
EPS (Diluted)	-0.89	-0.59	-6.64	-0.34	-0.29
Free Cash Flow	-11.42	-7.41	-1.59	-0.4	-0.8
Free Cash Flow Per Share	-0.66	-0.53	-0.43	-0.12	-0.24
EBITDA	-15.39	-8.22	-24.2	-1.03	-0.84
Depreciation & Amortization	0.01	0	0	0	0
EBIT	-15.4	-8.22	-24.2	-1.03	-0.84

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).